First AI-Developed Vaccine Tests Protection Against Future Pandemics

A team of scientists from the University of Cambridge has achieved a world first by developing a vaccine designed entirely by artificial intelligence, intended to provide protection against a broad range of coronaviruses. This innovation could revolutionise the way we prepare for future pandemics.

The experimental vaccine was designed to target the entire coronavirus family, including all existing COVID-19 variants, as well as viruses currently circulating amongst animals that could trigger the next pandemic. This approach represents a fundamental shift in the strategy for preventing infectious diseases.

To develop this groundbreaking vaccine, researchers used known genetic codes from multiple coronaviruses, which they analysed using artificial intelligence software. The AI system then designed a "super antigen" capable of training the human immune system to recognise and combat a wide range of viruses, even in the event of mutations or animal-to-human transmission.

Safety confirmed in first human trial

Clinical trials conducted between December 2021 and September 2023 involved 39 volunteers and were designed to assess the vaccine's safety. The results were encouraging — the vaccine was well tolerated across all four administered doses, with no significant safety concerns recorded.

Professor Jonathan Heeney from the University of Cambridge highlighted the significance of this achievement, explaining that this is the first time an antigen created by artificial intelligence has been tested on humans. This approach aims to create vaccines that protect us not only against current viruses, but also against those that could cause the next epidemic.

Although the impact on the immune system was modest, the findings continue to generate enthusiasm within the scientific community. The team is simultaneously developing similar vaccines to combat influenza and the Ebola virus, using the same AI technology.

This innovation comes in response to a persistent challenge in vaccine development: the ability of viruses to alter their appearance through genetic mutations, which can render vaccines rapidly obsolete. This is why vaccines against COVID-19 and seasonal influenza must be updated on a regular basis.

For older people and vulnerable individuals, who face the greatest risk during pandemics, this development could offer more durable and comprehensive protection against future infectious diseases.